Abstract: Insecticide composition where the active ingredient includes a combination of at least one synthetic insecticidal molecule from the neonicotinoïd family, and at least one synergistic agent, which is chosen among the insect repellent agents and present in the composition at a molar ratio of the synergistic agent to the synthetic insecticidal molecule in the composition comprised between 0.001 and 0.2. The insecticide includes a synergistic combination of DEET or IR3535® with thiaclopride or thiamethoxam that are more effective at low doses.

Abstract: The present invention relates to compounds of formula (III) or to compounds of formula (IV) wherein R1, R2, R3 and R4 are as defined in the claims, and their use in therapeutic treatments of 5-lipoxygenase related diseases such as chronic airway inflammatory or dermatological disorders.

Abstract: The present invention is in the technical field of breast cancer management, and more particularly relates to the diagnosis of breast cancer. The invention is more particularly based on the finding that specific biomarkers (olfactomedin-4, neudesin and desmoplakin) are abberantly expressed in the blood of breast cancer patients.

Abstract: A method for preventing, controlling or treating a fungal infection on a plant organ includes applying to the plant organ a non-fungicidal amount or a potentiating amount of a composition including a potentiating agent of a plant defense molecule, in association with a phytopharmaceutical vehicle.

Abstract: Insecticide composition wherein the active ingredient comprises the combination of a neonicotinoid insecticide, thiamethoxam as synthetic insecticide molecule, and at least one synergistic agent, which is chosen among the insect repellent agents such as DEET and/or IR3535® and present at a molar ratio of said synergistic agent to thiamethoxam comprised between O.OOI and 0.2 in the composition. Synergistic effect is observed at low doses. Use of the insecticide composition wherein said composition is sprayed or deposited on, or impregnated to a support, such as net, fabrics, cloth or tent, in the fight against insects which are harmful to human, to animals and/or to crops, and in particular against pyrethroid, carbanate and/or organophosphate resistant mosquitoes.

Abstract: Disclosed are methods for determining whether a patient will achieve a response after radiation therapy, in particular a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy including the steps of i) determining the level of ceramide in a first blood sample obtained from the patient before radiation therapy, ii) determining the level of ceramide in a second blood sample obtained from the patient during or just after radiation therapy, iii) comparing the level determined at step i) with the level determined at step ii) and iv) concluding that the patient will achieve response when the level determined at step ii) is higher than the level determined at step i) or concluding that the patient will not achieve a response when the level determined at step ii) is lower than the level determined at step i).

Abstract: A measurement instrument, i.e. a mobile body, measures distances between a current position of the mobile body and obstacles in the environment of the mobile body by: a) taking at least N measurements of distances between the mobile body and the obstacles, by consecutive angular steps of A/N (A is a predetermined angular sector), and combining the distances with the respective angular steps in order to establish map data; b) moving the mobile body and repeating step a) for a new current position of the mobile body; and c) simultaneously determining, according to the distances measured for each angular step of the current position of step b) and the preceding position of step a), the current position of the mobile body in step b) on the map relative to the initial position thereof in step a), and new data of the map.

Abstract: A method for assessing the presence and/or the severity of a lesion in an organ or tissue of a subject through automated analysis of at least one image of the organ or tissue is provided. In particular, the organ or tissue is a liver organ or liver tissue. The method includes the calculation of a score that combines descriptors of the image, and includes the steps of: a) measuring on the image at least two descriptors of the image, b) mathematically combining the descriptors in a score; and c) assessing the presence and/or the severity of a lesion in the organ or tissue based on the value of the score calculated at step b).

Abstract: The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.

Abstract: A method for displaying at least two medical images, each medical image highlighting at least one feature, including steps of obtaining a 2D medical image, identifying at least two features on the obtained medical image, generating masks showing the identified features, each mask highlighting at least one of the identified features, generating a set of at least two medical images, each medical image highlighting at least one of the identified features by superimposing at least one of the masks on the obtained medical image, and displaying the set of at least two generated medical images, one after the other. The invention also relates to a microprocessor comprising a computer algorithm to perform the method of the invention and to a system comprising said microprocessor and a visualizing means.

Abstract: The present invention relates to a method for preparing poloxamer-protein particles. It also relates to poloxamer-protein particles obtainable by this method, dispersion thereof, and their use in methods of encapsulation, in particular of microencapsulation.

Abstract: The invention disclosed herein relates to the field of epidermal repair and skin innate immunity. More particularly, the invention concerns the use of a mix of cytokines to inhibit keratinocyte differentiation, activate skin innate immunity, increase the expression of anti-microbial peptides, and improve epidermal repair. In particular, the invention concerns compositions comprising at least IL-17, TNF? and OSM that can be formulated for topical administration for cosmetic or dermatologic use.

Abstract: Method for providing a reliable non-invasive diagnostic test of the presence and/or severity of a disease, and associated software and expert system includes: a. collecting a diagnostic index, called Initial Index, preferably a score, b. calculating the Dispersion Index of the collected Initial Index, c. analyzing the reliability of each data by identifying if at least one data of index collected in step a) is an abnormal, inconsistent and/or a non-homogeneous data, or is responsible for a greater decrease in the Dispersion Index than that observed with other data, d. if a data is an abnormal, inconsistent and/or non-homogeneous data, or a data lowering a Dispersion Index, generating an Event Alert, e. if an Event Alert is generated, calculating new indexes, f. replacing the Initial Index including an abnormal, inconsistent and/or non-homogeneous data or a data affecting the Dispersion Index, with an Alternative, Estimated or a Mixed Index.

Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.

Abstract: The present invention relates to a method for assessing the presence and/or the severity of a lesion in an organ or tissue of a subject through automated analysis of at least one image of said organ or tissue, wherein said organ or tissue is preferably a liver organ or liver tissue, comprising the calculation of a score combining descriptors of said image, wherein said method comprises the steps of: a. measuring on said at least one image at least two descriptors of said at least one image; b. mathematically combining said at least two descriptors in a score; and c. assessing the presence and/or the severity of a lesion in the organ or tissue based on the value of the score calculated at step (b).

Abstract: An ionic liquid supported organotin reagent of formula (I) A process for manufacturing the ionic liquid supported organotin reagent of formula (I), a process for manufacturing an halogenated or radio-halogenated compound using compound of formula (I), a device for implementing the halogenating process and a kit including the compound of formula (I) are also described.

Abstract: A method for assessing turbulence parameters of a medium comprises the following steps: the illumination, by a laser beam being propagated in said medium, of a film of photochromic organic material that can comprise molecules of azobenzene, or of spyropyrane, or of stilbene, or of coumarin, or of fulgide, said illumination creating a surface grating in said film comprising scratches, the deformations of which are a function of the turbulence parameters; a step of acquisition of images comprising individual areas of structures linked to said scratches, more or less reduced and representative of the turbulence parameters of said medium; a step of processing of said images that makes it possible to assess the turbulence parameters of said medium. A device is also provided.

Abstract: This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said data being selected from the group consisting of medical imaging data and clinical measurements, said combination being performed through a mathematical function. This invention also relates to a method wherein the combination through a mathematical function, of at least one blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, is performed at least twice and the at least two resulting scores are combined in an algorithm based on the diagnostic reliable intervals.

Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.

Abstract: The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS40-63 peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS40-63 peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.